Disease-modifying therapies for Parkinson’s disease
"The biggest benefit in working with Spinverse was that they are very familiar with the application process and advised us on how to formulate our project to meet EIC Accelerator’s expectations and requirements. Spinverse also challenged us to focus on the right things in our project, which for its part led to the successful outcome."
Antti Vuolanto, CEO, Herantis Pharma.
Customer story in numbers
MILLION € (total budget)
European Innovation Council Accelerator
The ReTreatPD project by Herantis Pharma Plc will focus on preparations towards a Phase 2 clinical study with HER-096 in conjunction with Parkinson’s disease (PD). The project includes development of biomarkers for monitoring target engagement and treatment response to the HER-096 molecule.
The company is delighted to advance their biomarker development with this funding as recent developments have shown that biomarkers play an increasingly important role in clinical trial design for CNS drug candidates. The current dopamine substitution treatments alleviate some of the symptoms, however, there is no cure for PD nor any disease-modifying therapies.
How we reached the goals
Spinverse team was guiding Herantis Pharma Plc on their path to the successful outcome in the competitive funding application process by providing support in project planning, application writing and pitching.
Herantis has developed a new pharmaceutical HER-096, able to affect PD pathology and potential to revolutionise the treatment of PD, alleviating the huge burden it now causes patients and healthcare.
Impact of the project
The potential of the project outcome is to slow down or even stop the disease progression, which the currently available treatments cannot do.